6. Indian Pharmaceutical
Evolution
6
Phase II
Government Control
•Indian Patent Act –
1970
•Drug prices
capped
•Local companies
begin to make an
impact
Phase III
Development
Phase
•Process
development
•Production
infrastructure
creation
•Export initiatives
Phase IV
Growth Phase
•Rapid expansion
of domestic market
•International
market
development
•Research
orientation
Phase V
Innovation and
Research
•New IP law
•Discovery Research
•Convergence
1970 1980 1990 2000 2010
Phase I
Early Years
•Market share
domination by
foreign
companies
•Relative
absence of
organized Indian
companies
7. India Market
• India saw its first pharmaceutical company in 1930,
Bengal Chemicals and Pharmaceuticals works
• Till 1970s Indian pharmaceutical market was non
existent
• Indian Pharmaceutical market currently stands at
approximately 23.6 bn USD**
• 10500 manufacturing units, 3000 pharma
companies*
7
8. Interesting Facts
• Branded generics dominate the retail market with
70-80% share
• Price levels and margins are low due to intense
competition
• India ranks 10th globally in terms if value, 3rd in terms
of volume
• Last 5 years the growth rate is ranging between 13-
14% as compared to 9% before that
8
11. Opportunities
• As per 'Pharma Vision 2020', the Government of India aims to
make India a global leader in end-to-end drug
manufacturing**
• Manufacturing costs in India are approximately 35-40 per cent
of those in the US due to low installation and manufacturing
costs**
• The biologics market will grow to 3 bn USD by 2020*
• The projected human resource requirement in the Indian
pharma sector is estimated to be about 21,50,000 by 2020**
• Industry Least affected by recession
11
12. Opportunities Contd.
• Due to increasing population and income levels,
demand for high-end drugs is expected to reach US$ 8
billion by 2015
• Expenditure on pharmaceuticals is likely to increase to
over 40 per cent of the total spending on healthcare by
households by 2015 from 28 per cent in 2007
• With 70 per cent of India's population residing in rural
markets, various pharma companies are investing in the
distribution network in rural areas
• Increased penetration of chemists, especially in the rural
parts of the country would make OTC drugs easily
available
12
